Strong 5-aminolevulinic acid-induced fluorescence is a novel intraoperative marker for representative tissue samples in stereotactic brain tumor biopsies

Stereotactic biopsies represent a routine neurosurgical procedure for the diagnosis of intracranial lymphomas and selected diffusely infiltrating gliomas. Acquisition of tissue samples that do not allow correct tumor typing and grading is, however, not uncommon. Five-aminolevulinic acid (5-ALA) has been shown to accumulate in malignant tumor tissue. The aim of this study was to prospectively investigate the clinical usability of 5-ALA for intraoperative detection of representative tissue in stereotactic tumor biopsies. Fifty consecutive patients underwent frameless stereotactic biopsy for a suspected brain tumor. 5-ALA was administered 4 h before anesthesia. Serial biopsy samples were obtained and intraoperatively checked for 5-ALA fluorescence (strong, vague, or none) using a modified neurosurgical microscope. All samples were examined for the presence of representative tumor tissue according to neuroimaging (MRI, positron emission tomography, and/or chemical shift imaging) and histopathological parameters. Visible 5-ALA fluorescence was observed in 43/50 patients (strong in 39 and vague fluorescence in four cases). At biopsy target, 52/53 samples of glioblastomas, 9/10 samples of gliomas grade III, and 14/16 samples of lymphomas revealed strong 5-ALA fluorescence. Samples with strong 5-ALA fluorescence were only observed at, but not outside the biopsy target. All tissue samples with strong 5-ALA fluorescence were representative according to our neuroimaging and histopathological criteria (positive predictive value of 100%). Our data indicate that strong 5-ALA fluorescence is a reliable and immediately available intraoperative marker of representative tumor tissue of malignant gliomas and intracranial lymphomas in stereotactic biopsies. Thereby, the application of 5-ALA in stereotactic brain tumor biopsies may in future reduce costs for operating room and neuropathology and may decrease procedure-related morbidity.

[1]  Z L Gokaslan,et al.  Limitations of stereotactic biopsy in the initial management of gliomas. , 2001, Neuro-oncology.

[2]  C. Avezaat,et al.  Safety and efficacy of frameless and frame-based intracranial biopsy techniques , 2008, Acta Neurochirurgica.

[3]  F. Zanella,et al.  Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. , 2006, The Lancet. Oncology.

[4]  G von Campe,et al.  5-aminolevulinic acid induced protoporphyrin IX fluorescence in high-grade glioma surgery: a one-year experience at a single institutuion. , 2008, Swiss medical weekly.

[5]  Johan M. Kros,et al.  Towards improving the safety and diagnostic yield of stereotactic biopsy in a single centre , 2010, Acta Neurochirurgica.

[6]  M. Eljamel.  Which intracranial lesions would be suitable for 5-aminolevulenic acid-induced fluorescence-guided identification, localization, or resection? A prospective study of 114 consecutive intracranial lesions. , 2009, Clinical neurosurgery.

[7]  Stefan Wolfsberger,et al.  Anatomical landmarks for image registration in frameless stereotactic neuronavigation , 2002, Neurosurgical Review.

[8]  Heinrich Lanfermann,et al.  Stereotactic Biopsy in Gliomas Guided by 3-Tesla 1H-Chemical-Shift Imaging of Choline , 2008, Stereotactic and Functional Neurosurgery.

[9]  N. Altınörs,et al.  The accuracy and diagnostic yield of computerized tomography guided stereotactic biopsy in brain lesions. , 2008, Turkish neurosurgery.

[10]  K. Ceyhan,et al.  An analysis of stereotactic biopsy of brain tumors and nonneoplastic lesions: a prospective clinicopathologic study. , 2005, Surgical neurology.

[11]  A. Belli,et al.  Image-guided frameless stereotactic biopsy without intraoperative neuropathological examination. , 2010, Journal of neurosurgery.

[12]  S. Goldman,et al.  Combined use of 18F-fluorodeoxyglucose and 11C-methionine in 45 positron emission tomography-guided stereotactic brain biopsies. , 2004, Journal of neurosurgery.

[13]  R. Grossman,et al.  Haemorrhagic complications and the incidence of asymptomatic bleeding associated with stereotactic brain biopsies , 2005, Acta Neurochirurgica.

[14]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[15]  Alessandro Olivi,et al.  Accuracy of frameless and frame-based image-guided stereotactic brain biopsy in the diagnosis of glioma: comparison of biopsy and open resection specimen , 2005, Neurological research.

[16]  J. Tilgner,et al.  Validation of Intraoperative Diagnoses Using Smear Preparations from Stereotactic Brain Biopsies: Intraoperative versus Final Diagnosis—Influence of Clinical Factors , 2005, Neurosurgery.

[17]  T. Hakan,et al.  Accuracy and diagnostic yield of stereotactic biopsy in the diagnosis of brain masses: Comparison of results of biopsy and resected surgical specimens , 2005, Neuropathology : official journal of the Japanese Society of Neuropathology.

[18]  I. Yang.  5-Aminolevulinic Acid Is a Promising Marker for Detection of Anaplastic Foci in Diffusely Infiltrating Gliomas With Nonsignificant Contrast Enhancement , 2011 .

[19]  W. Stummer,et al.  Technical Principles for Protoporphyrin-IX-Fluorescence Guided Microsurgical Resection of Malignant Glioma Tissue , 1998, Acta Neurochirurgica.

[20]  Eljamel Ms.  Which intracranial lesions would be suitable for 5-aminolevulenic acid-induced fluorescence-guided identification, localization, or resection? A prospective study of 114 consecutive intracranial lesions. , 2009 .

[21]  K. Takakura,et al.  Low-Grade Glioma on Stereotactic Biopsy: How Often is the Diagnosis Accurate? , 2008, Minimally invasive neurosurgery : MIN.

[22]  Jacques J. Morcos,et al.  Outcomes and Management Strategies after Nondiagnostic Stereotactic Biopsies of Brain Lesions , 2009, Stereotactic and Functional Neurosurgery.

[23]  Ajay Niranjan,et al.  Establishing a Benchmark for Complications Using Frame-Based Stereotactic Surgery , 2008, Stereotactic and Functional Neurosurgery.

[24]  D. Louis.  WHO classification of tumours of the central nervous system , 2007 .

[25]  M L Apuzzo,et al.  Role of stereotactic biopsy in the diagnosis and management of brain tumors. , 1998, Seminars in surgical oncology.

[26]  W. Hall.  The safety and efficacy of stereotactic biopsy for intracranial lesions , 1998, Cancer.

[27]  Walter A Hall,et al.  Intraoperative MR‐guided neurosurgery , 2008, Journal of magnetic resonance imaging : JMRI.

[28]  Thomas Czech,et al.  Value of 1H-magnetic resonance spectroscopy chemical shift imaging for detection of anaplastic foci in diffusely infiltrating gliomas with non-significant contrast-enhancement , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[29]  C. Marosi,et al.  [11C] Methionine and [18F] Fluorodeoxyglucose PET in the follow-up of glioblastoma multiforme , 2007, Journal of Neuro-Oncology.

[30]  Deepali Jain,et al.  Correlation of diagnostic yield of stereotactic brain biopsy with number of biopsy bits and site of the lesion , 2006, Brain Tumor Pathology.

[31]  A. Lozano,et al.  Incidence of silent hemorrhage and delayed deterioration after stereotactic brain biopsy , 1998 .

[32]  O Ganslandt,et al.  Frameless Stereotactic Brain Biopsy Procedures Using the Stealth Station: Indications, Accuracy and Results , 2003, Zentralblatt fur Neurochirurgie.

[33]  Witham,et al.  Comprehensive assessment of hemorrhage risks and outcomes after stereotactic brain biopsy. , 2001, Journal of neurosurgery.

[34]  S. Goldman,et al.  Stereotactic brain biopsy guided by positron emission tomography (PET) with [F-18]fluorodeoxyglucose and [C-11]methionine. , 1997, Acta neurochirurgica. Supplement.

[35]  J. Torner,et al.  Computed imaging-assisted stereotactic brain biopsy: a risk analysis of 225 consecutive cases. , 1998, Surgical neurology.

[36]  L D Lunsford,et al.  Complications of stereotactic brain surgery. , 1998, Neurologic clinics.

[37]  D. Thomas,et al.  The advantages of frameless stereotactic biopsy over frame-based biopsy , 2002, British journal of neurosurgery.

[38]  M. Mittler,et al.  Stereotactic brain biopsies and operative complications: technique to further decrease risks , 2005, Acta Neurochirurgica.

[39]  H Stepp,et al.  Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients. , 2000, Journal of neurosurgery.